Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities

Details

The offers include multiple series of senior notes and debentures due between 2026 and 2050, with varying interest rates and offer subcaps. The tender offers will expire on March 11, 2026, unless extended. Early tender deadline is February 24, 2026. The company is offering different consideration amounts based on the acceptance priority levels of the securities. The Offer to Purchase document, which contains the full terms and conditions of the offers, is being distributed to holders.

Items reported

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.